A neurosurgeon recently shared on social media how a simple blood test might detect brain diseases years before symptoms appear. The Neurofilament Light Chain (NfL) test measures protein fragments released when brain or spinal cord cells are damaged. Elevated NfL levels are linked to conditions like Alzheimer's, Parkinson's, multiple sclerosis, stroke, and traumatic brain injury. The test involves a basic blood draw and can detect silent brain damage long before imaging or symptoms reveal problems. Experts confirm that NfL is a sensitive marker for neuronal injury and can indicate faster disease progression. However, it is not disease-specific and cannot pinpoint the exact cause alone. The test is now available through commercial laboratories, but routine population screening is not standard practice. Doctors recommend it mainly for individuals with symptoms, strong family history, or clear risk factors for neurological conditions.
Understanding NfL and Its Clinical Limitations
According to medical experts, elevated NfL reflects ongoing neuronal injury and is among the most sensitive blood markers for brain damage. Higher levels are associated with faster decline in disorders like Parkinson's disease and Alzheimer's-related syndromes. However, the test has limitations. A raised NfL value indicates that neurons are being damaged but does not identify the specific cause or provide a firm diagnosis. Its best use is as part of a broader assessment that includes clinical evaluation, imaging, and other biomarkers. Doctors recommend testing for individuals with concerning symptoms, objective findings, or strong family history where knowing neuronal injury trajectory would influence treatment decisions.
Source: Link